Sanofi-aventis Phase III study of Lixisenatide meets primary endpoint
Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. Sanofi-aventis claims that GetGoal-X is the first head-to-head study
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.